- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00528320
Clinical Evaluation of Cardiac Resynchronization Therapy (CRT) Using the Ovatio CRT Implantable Cardioverter-defibrillator (ICD) System
Clinical Evaluation of Cardiac Resynchronization Therapy With Implantable Cardioverter-defibrillator Therapy
This study provides a continued access registry for cardiac resynchronization therapy with defibrillation (CRT-D), which helps to resynchronize (coordinate) the rhythm of the heart by helping the left ventricle contract (pump blood) more uniformly, in patients with severe heart failure (New York Heart Association [NYHA] Class III or IV).
Quality of life, adverse events and device success will be analyzed and reported.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
ICDs have been shown to increase life expectancy substantially over various drug regimens in patients with life threatening ventricular arrhythmias. Furthermore, large scale studies of cardiac resynchronization therapy in ICD-indicated heart failure patients have demonstrated improvements in functional capacity and quality of life, without unacceptable increases in morbidity or mortality.
This study provides a continued access registry for cardiac resynchronization therapy with defibrillation (CRT-D), which helps to resynchronize (coordinate) the rhythm of the heart by helping the left ventricle contract (pump blood) more uniformly, in patients with severe heart failure (NYHA Class III or IV).
Quality of life, adverse events and device success will be analyzed and reported.
Type d'étude
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Accepted indication for ICD implant
- Severe heart failure (NYHA Class III or IV) at the time of enrollment
- May have pre-existing ICD, provided subject is on stable, optimal medical regime
- Sinus rhythm with spontaneous QRS duration greater than or equal to 150 ms, or a QRS duration greater than or equal to 130 ms with an inter-ventricular mechanical delay (IVMD) greater than or equal to 40 ms
- Left-ventricular ejection fraction (LVEF) of 35% or less
Exclusion Criteria:
- Any generally accepted indication for standard cardiac pacing, or any contraindication for standard cardiac pacing
- Any contraindication for ICD therapy
- Currently implanted with a lead positioned in or through the coronary sinus
- Hypertrophic or obstructive cardiomyopathy
- Acute myocarditis
- Unstable coronary symptoms (unstable angina or myocardial infarction) within the last month
- Recent or planned cardiac revascularization or coronary angioplasty
- Correctable valvular disease that is the primary cause of heart failure
- Mechanical tricuspid valve
- Chronic atrial arrhythmia or cardioversion for atrial fibrillation within the past month, or paroxysmal atrial fibrillation requiring new pharmacologic therapy within the past month
- Systolic blood pressure consistently above 170 mmHg or consistently below 80 mmHg
- Supine resting heart rate exceeding 100 bpm
- Receiving continuous IV infusion of positive inotropic therapy or intermittent therapy (IV infusion) more than twice per week
- Heart transplant recipient
- Primary pulmonary disease of a severity that might limit the patient's ability to perform a treadmill test
- Serum creatinine above 3.0 mg/dL
- Serum hepatic functions at or above three times the upper normal limit
- Cerebrovascular event within the previous three months
- Inability to walk or other physical impediments which might prevent the patient from completing a maximum, symptom-limited treadmill test
- Age of less than 18 years
- Pregnancy
Plan d'étude
Comment l'étude est-elle conçue ?
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ITAC06
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Ovatio CRT
-
LivaNovaComplétéTachycardies biventriculairesFrance, Italie, Royaume-Uni, Allemagne, Le Portugal, Belgique, Canada, Espagne, Suède
-
LivaNovaComplétéTachycardieFrance, Allemagne, Le Portugal, Italie, Canada, États-Unis, Belgique, Pays-Bas, Royaume-Uni
-
ELA Medical, Inc.ComplétéMort cardiaque subiteÉtats-Unis
-
Medtronic Cardiac Rhythm and Heart FailureMedtronicComplétéInsuffisance cardiaqueInde
-
Children's Hospital of PhiladelphiaThe Hilda & Preston Davis FoundationComplétéAnorexie nerveuseÉtats-Unis
-
Inova Health Care ServicesMedtronicActif, ne recrute pasBloc de branche gauche | Insuffisance cardiaque (IC) | Fraction d'éjection ventriculaire gaucheÉtats-Unis
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonPas encore de recrutement
-
University Hospital OlomoucPas encore de recrutement
-
CMC Ambroise ParéRetiréComparer deux modalités de programmation pour les appareils CRT chez les patients souffrant d'insuffisance cardiaque avec une indication pour la thérapie de resynchronisation cardiaqueMonaco, France
-
Montreal Heart InstituteCanadian Institutes of Health Research (CIHR); Abbott Medical DevicesRésiliéInsuffisance cardiaqueCanada